GSK has announced that it will acquire US-based oncology specialist TESARO for $5.1 billion, gaining access to its PARP inhibitor Zejula (niraparib). Previously, several other firms were rumoured ...

has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal cancer. Following a period of restricted access, the once-a-day capsule will ...

GSK (NYSE:GSK) reported mixed results from a Phase 3 study evaluating Zejula, or niraparib, and Jemperli, or dostarlimab, in the treatment of advanced ovarian cancer. The U.K. drugmaker said that ...

along with providing access to new scientific capabilities,” says GSK CEO Emma Walmsley in the release. TESARO’s drug Zejula is a PARP inhibitor approved for treating ovarian cancer. PARP inhibitors ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 53 cents. Core earnings declined 20% year over year ...

GlaxoSmithKline said it will raise prices ... its recently acquired cancer drug Zejula and on several products in its HIV-focused ViiV joint venture, according to 3 Axis Advisors.

To offer further encouragement, Dame Emma Walmsley, the company’s chief, offered a more optimistic outlook than expected for ...

GSK plc GSK reported fourth-quarter 2024 core ... it received approval in the EU in January 2024. Zejula sales fell 3% in the quarter. Though the drug’s U.S. sales were adversely impacted ...